RETRACTED: WORSENING OF PRE-EXISTING VALVULOPATHY WITH A NEW OBESITY DRUG LORCASERIN, A SELECTIVE 5-HYDROXYTRYPTAMINE 2C RECEPTOR AGONIST: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal ( http://www.elsevier.com/locate/withdrawalpolicy ). In currently published abstract, it was mentioned that the authors measured “change in degree of pre-existing valvulopathy”. Actually, what they measured was “increase in valvular regurgitant grade from baseline” in a normal valve without any evidence of pre-existing FDA-defined valvulopathy. The studies included in their meta-analysis excluded patients with FDA-defined valvulopathy. Therefore, the outcome in their current abstract “increase in pre-existing AR” is actually “increase in aortic regurgitant grade from baseline” in patients without pre-existing FDA-defined aortic regurgitation. Similarly, the outcome in their current abstract “increase in pre-existing MR” is actually “increase in mitral regurgitant grade from baseline” in patients without pre-existing FDA-defined mitral regurgitation. Study data and statistical analysis is correct as it is. The results of their meta-analysis demonstrate that the increase in aortic regurgitant grade from baseline was significantly higher in patients on lorcaserin compared to placebo. The increase in mitral regurgitant grade from baseline was not different between both groups. The interpretation of rest of the outcomes is correct as it is.